Browse by UCL people
Group by: Type | Date
Jump to: Article | Conference item
Number of items: 16.
Article
Bhamani, A;
Katsampouris, E;
Bojang, F;
Verghese, P;
Creamer, A;
Prendecki, R;
Khaw, CR;
... Quaife, SL; + view all
(2025)
Uptake and 4-week outcomes of an ‘opt-out’ smoking cessation referral strategy in a London-based lung cancer screening setting.
BMJ Open Respiratory Research
, 12
(1)
, Article e002337. 10.1136/bmjresp-2024-002337.
|
|
Bhamani, Amyn;
Creamer, Andrew;
Verghese, Priyam;
Prendecki, Ruth;
Horst, Carolyn;
Tisi, Sophie;
Hall, Helen;
... SUMMIT consortium, .; + view all
(2025)
Low-dose CT for lung cancer screening in a high-risk population (SUMMIT): a prospective, longitudinal cohort study.
The Lancet Oncology
10.1016/S1470-2045(25)00082-8.
(In press).
|
|
Creamer, Andrew W;
Horst, Carolyn;
Dickson, Jennifer L;
Tisi, Sophie;
Hall, Helen;
Verghese, Priyam;
Prendecki, Ruth;
... Janes, Sam M; + view all
(2024)
Stage at Diagnosis Following Delay to Interval Scans for Indeterminate Nodules in Lung Cancer Screening: An Observational Study Examining the Outcomes of CHEST Expert Panel Recommendations.
Chest
, 165
(4)
pp. 1020-1024.
10.1016/j.chest.2023.10.033.
|
|
Elyashiv, O;
Ledermann, J;
Parmar, G;
Farrelly, L;
Counsell, N;
Feeney, A;
El-Khouly, F;
... Nicum, S; + view all
(2020)
ICON 9-an international phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy.
International Journal of Gynecologic Cancer
10.1136/ijgc-2020-002073.
(In press).
|
 |
|
Embleton-Thirsk, A;
Deane, E;
Townsend, S;
Farrelly, L;
Popoola, B;
Parker, J;
Rustin, G;
... Kaplan, R; + view all
(2019)
Impact of retrospective data verification to prepare the ICON6 trial for use in a marketing authorization application.
Clinical Trials
, 16
(5)
pp. 502-511.
10.1177/1740774519862528.
|
|
|
Fennell, D;
Danson, S;
Woll, P;
Forster, M;
Talbot, D;
Child, J;
Farrelly, L;
... Wheeler, G; + view all
(2020)
Ganetespib in combination with pemetrexed-platinum chemotherapy in patients with pleural Mesothelioma (MESO-02): A phase Ib trial.
Clinical Cancer Research
, 26
(18)
pp. 4748-4755.
10.1158/1078-0432.CCR-20-1306.
|
|
Fenwick, JD;
Landau, DB;
Baker, AT;
Bates, AT;
Eswar, C;
Garcia-Alonso, A;
Harden, SV;
... Counsell, N; + view all
(2020)
Long-Term Results from the IDEAL-CRT Phase 1/2 Trial of Isotoxically Dose-Escalated Radiation Therapy and Concurrent Chemotherapy for Stage II/III Non-small Cell Lung Cancer.
International Journal of Radiation Oncology*Biology*Physics
, 106
(4)
pp. 733-742.
10.1016/j.ijrobp.2019.11.397.
|
|
|
Kurtz, JE;
Gebski, V;
Sukhin, V;
Carey, M;
Kong, I;
Glasspool, RM;
Berek, JS;
... Friedlander, M; + view all
(2021)
Incorporating patient centered benefits as endpoints in randomized trials of maintenance therapies in advanced ovarian cancer: A position paper from the GCIG symptom benefit committee.
Gynecologic Oncology
, 161
(2)
pp. 502-507.
10.1016/j.ygyno.2021.02.018.
|
|
Ledermann, JA;
Embleton, AC;
Raja, F;
Perren, TJ;
Jayson, GC;
Rustin, GJS;
Kaye, SB;
... Collaborators, I; + view all
(2016)
Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial.
Lancet
, 387
(10023)
pp. 1066-1074.
10.1016/S0140-6736(15)01167-8.
|
|
Ledermann, JA;
Embleton-Thirsk, AC;
Perren, TJ;
Jayson, GC;
Rustin, GJS;
Kaye, SB;
Hirte, H;
... ICON6 collaborators, .; + view all
(2021)
Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial.
ESMO Open
, 6
(2)
, Article 100043. 10.1016/j.esmoop.2020.100043.
|
|
|
Marth, C;
Tarnawski, R;
Tyulyandina, A;
Pignata, S;
Gilbert, L;
Kaen, D;
Rubio, MJ;
... Makker, V; + view all
(2022)
Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001.
International journal of gynecological cancer: official journal of the International Gynecological Cancer Society
, 32
(1)
pp. 93-100.
10.1136/ijgc-2021-003017.
|
|
|
McCormack, Mary;
Eminowicz, Gemma;
Gallardo, Dolores;
Diez, Patricia;
Farrelly, Laura;
Kent, Christopher;
Hudson, Emma;
... Ledermann, Jonathan Andrew; + view all
(2024)
Induction chemotherapy followed by standard chemoradiotherapy versus standard chemoradiotherapy alone in patients with locally advanced cervical cancer (GCIG INTERLACE): an international, multicentre, randomised phase 3 trial.
The Lancet
, 404
(10462)
pp. 1525-1535.
10.1016/S0140-6736(24)01438-7.
|
|
Oza, AM;
Cook, AD;
Pfisterer, J;
Embleton, A;
Ledermann, JA;
Pujade-Lauraine, E;
Kristensen, G;
... ICON7, trial investigators; + view all
(2015)
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.
Lancet Oncology
, 16
(8)
pp. 928-936.
10.1016/S1470-2045(15)00086-8.
|
|
|
Vergote, I;
Gonzalez-Martin, A;
Lorusso, D;
Gourley, C;
Mirza, MR;
Kurtz, JE;
Okamoto, A;
... Zhu, J; + view all
(2022)
Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup.
The Lancet Oncology
, 23
(8)
e374-e384.
10.1016/S1470-2045(22)00139-5.
|
|
Vivekanandan, S;
Landau, DB;
Counsell, N;
Warren, DR;
Khwanda, A;
Rosen, SD;
Parsons, E;
... Fenwick, JD; + view all
(2017)
The Impact of Cardiac Radiation Dosimetry on Survival After Radiation Therapy for Non-Small Cell Lung Cancer.
International Journal of Radiation Oncology Biology Physics
, 99
(1)
pp. 51-60.
10.1016/j.ijrobp.2017.04.026.
|
|
Conference item
|
Embleton, AC;
Clark, E;
Townsend, S;
Farrelly, L;
Jones, C;
Kaplan, R;
(2015)
Impact of retrospective data verification on the results of the academic-led ICON6 trial.
Presented at: 3rd International Clinical Trials Methodology Conference, Glasgow, UK.
|
|
